- $186.70m
- $118.29m
- $7.67m
Brief: Adagene Reports Full Year 2021 Financial Results
Adagene's U.S. shares gain on collaboration pact with Sanofi
Brief: Adagene Announces Safebody Multi-Target Collaboration With Sanofi
Brief: Adagene Announces First Patient Dosed With Novel, Proprietary Combination Of Anti-Cd137 Agonist, Adg106, And Anti-Ctla-4 Monoclonal Antibody, Adg116
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Brief: Adagene Achieves Key Milestone In Collaboration With Exelixis For SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates
Brief: Adagene Presents Clinical Data Demonstrating Strong Safety And Early Signals Of Efficacy In Cold Tumors Including Pancreatic And Ovarian Cancers For Anti-Ctla-4 Monoclonal Antibody, Adg116, At Esmo-Io 2021
Brief: Adagene Presents Clinical Data Demonstrating Strong Safety And Early Signals Of Efficacy In Treatment-Resistant Tumors For Anti-CTLA-4 Monoclonal Antibody, ADG116, At ESMO-IO 2021
U.S. STOCKS ON THE MOVE-Facebook, Tesla, Regeneron Pharma, ImmunoGen
Brief: Adagene Announces FDA Clearance Of Ind For Phase 1B/2 Trial Of Anti-CTLA-4 Monoclonal Antibody Adg116
Brief: Adagene Announces Presentations Of Data For Two Antibody Programs At ESMO Immuno-Oncology Congress 2021
Brief: Adagene Establishes Collaboration For Clinical Trial Of ADG106 In Combination With Nivolumab
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM
Brief: Adagene Inc - Cash And Cash Equivalents Were US$208.3 Mln As Of June 30, 2021, Compared To US$75.2 Mln As Of Dec. 31, 2020
Brief: Adagene Announces Third Clinical Trial Collaboration With Merck
Brief: Adagene Appoints Interim Chief Medical Officer
Brief: Adagene Announces Clinical Trial Collaboration With Merck